Tysabri and Progressive Multifocal Leukoencephalopathy: What the Evidence Shows About PML Timeline

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Literacy to Specialized Risk Assessment

If you or a loved one is taking Tysabri and concerned about PML, understanding the timeline of symptom onset and disease progression is critical. For decades, medical research has tracked the relationship between immunosuppressive therapies and opportunistic infections, building a body of evidence that informs current monitoring guidelines. This page summarizes what that evidence can and cannot tell us about the PML timeline after Tysabri exposure.

Tysabri and PML: A Critical Bridge to Occupational Risk

Tysabri (natalizumab) is a monoclonal antibody indicated as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease when response to conventional therapy is inadequate. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri highlighting this risk, emphasizing that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML and withhold dosing immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three primary risk factors for developing PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for PML, and these factors should be weighed against expected benefit when initiating or continuing therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of this risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Diagnosis of PML

The clinical presentation of PML can be subtle and may mimic multiple sclerosis relapses, making early diagnosis challenging. Symptoms often include progressive weakness, visual disturbances, cognitive decline, and coordination difficulties. Diagnosis typically relies on brain MRI findings and detection of JCV DNA in cerebrospinal fluid. The FDA label advises that an MRI scan should be obtained prior to initiating Tysabri in multiple sclerosis patients, as this baseline scan can help differentiate subsequent multiple sclerosis symptoms from PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For Crohn's disease patients, a baseline brain MRI may also be helpful, though pre-existing brain lesions are uncommon in this population (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Prognosis and Treatment for Severe PML after Tysabri

Prognosis for PML after Tysabri is poor, with the boxed warning stating that the infection "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Treatment for severe PML primarily involves supportive care and rapid restoration of immune function. In the context of Tysabri-associated PML, the mainstay of management is immediate discontinuation of the drug and, in some cases, plasma exchange to accelerate clearance of natalizumab from the circulation. However, immune reconstitution inflammatory syndrome (IRIS) can occur as the immune system recovers, potentially worsening neurological injury. There are no approved antiviral therapies specifically for JCV, so management focuses on controlling IRIS and providing supportive care.

Risk Factors and Monitoring Recommendations

The timeline between Tysabri exposure and documented harm varies. PML has been reported during treatment and also following discontinuation in patients who did not have findings suggestive of PML at the time of stopping therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The FDA label advises that patients should continue to be monitored for any new signs or symptoms that may be suggestive of PML for at least six months following discontinuation of Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This extended monitoring period reflects the potential for delayed onset of PML after drug cessation. Adequacy of warnings regarding Tysabri and PML is addressed through the boxed warning, which is the strongest safety communication the FDA can require. The warning clearly states that Tysabri increases PML risk, identifies known risk factors, and mandates immediate withholding of dosing at first suspicion of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, the TOUCH Prescribing Program restricts distribution to ensure prescribers and patients are informed of the risks and agree to monitoring protocols. Despite these measures, the severity of PML—often resulting in death or severe disability—underscores the gravity of this adverse effect.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the prognosis for PML after Tysabri treatment?

The prognosis for PML after Tysabri is poor, with the FDA boxed warning stating that the infection "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Treatment focuses on drug discontinuation and supportive care, but outcomes remain grave.

How is severe PML after Tysabri treated?

Treatment for severe PML primarily involves immediate discontinuation of Tysabri and, in some cases, plasma exchange to accelerate drug clearance. Supportive care is essential, and management of immune reconstitution inflammatory syndrome (IRIS) is critical, as there are no approved antiviral therapies for JCV (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Three primary risk factors have been identified: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed Label for Tysabri

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.